Livanova PLC reported results
SEC 8-KRead source ↗
Livanova PLC is a US-listed company in the health care equipment industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Model estimate per share
~$64
Valuation models combined (2)
Base case. Range ~$36–$77. Weighted average of 2 models (forward price-to-earnings vs peers, forward price-to-sales vs peers).
Price vs value
No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.
Livanova PLC valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders0 buying, 3 selling0 purchases and 7 sales by directors and officers, last 12 monthsInsider trades
- Funds168 adding, 120 cuttingOf 52 active managers that changed their stake, 23 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 15% in the quarter to 2026-06-30, the 4th beat in the last four quarters.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
- Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.
Things to watch
- Results due soon. Results are expected around 4 November; the share price can move sharply on the day.
- Heavily shorted. 12.9% of the shares available to trade are sold short (9.2 days of average volume to cover).
Latest results
- Earnings per share
- $1.26 against an average estimate of $1.09: beat by 15.1%
- Share reaction
- -11.2% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
- Next report
- November 4, 2026; average EPS estimate $1.06
Price chart
- 1 day+1.6%
- 1 week-0.5%
- 1 month+6.8%
- This year+30.4%
- 1 year+52.4%
- 5 years-10.6%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- August 5, 2026
- Next results (est.)
- November 4, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Results
Valuation models
We value Livanova PLC as an operating company, with every model that fits that kind of business. Cost of equity 9.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.03 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. | — | Does not apply: no revenue, margin or share count to start from |
| Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$77 ~$68–$120 | Included |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$36 ~$39–$140 | Included, half weight |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | ~$64 ~$36–$77 | 2 models |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Livanova PLC with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.
Forecasts and guidance
Next results: November 4, 2026, before the open. Analysts expect revenue of $381m and EPS of $1.06 (range $1.02 to $1.13) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | $4.36 | +12% | $1.5bn | +10% |
| Next | $4.68 | +8% | $1.6bn | +7% |
Next year's EPS estimate has moved +1.1% in 90 days, across 10 analysts.
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is +2.5% on 90 days ago. In the last 30 days, 9 analysts raised Livanova PLC's forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | $4.25 | $4.63 |
| 60 days ago | $4.36 | $4.68 |
| 30 days ago | $4.36 | $4.68 |
| 7 days ago | $4.36 | $4.68 |
| Now | $4.36 | $4.68 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | $1.09 | $1.26 | +15.1% |
| Mar 2026 | $0.90 | $0.98 | +9.3% |
| Dec 2025 | $0.81 | $0.86 | +5.6% |
| Sept 2025 | $0.92 | $1.11 | +20.4% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 12.9% of tradable shares
- Days to cover
- 9.21 at average volume
- Short interest, 1 month
- +15% to October 15, 2026
- Held by institutions
- — of shares
- Held by insiders
- 0.4% of shares
- Employees
- 3,300 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| LIVN | +32% | −37% | −7% | −11% | +33% | +30% |
| Industry peers (median) | −9% | −37% | −9% | −20% | −16% | −15% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| LIVN | 50% | 42% | 42% | 50% | 50% | 55% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| LIVN | −17% | −50% | −30% | −32% | −33% | −19% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 2, 2015: 74% from September 12, 2018 to April 8, 2025. Getting back needed a 287% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $49.57 – $85.33
- From 52-week high
- −6.0%
- vs 50-day average
- +2.1%
- vs 200-day average
- +9.9%
- Volatility (1 year)
- 36%
- Beta vs S&P 500
- 0.96
Share price after results
- Next day
- 6 up, 6 down typical move ±10.8%
- After a week
- 6 up, 6 down typical move ±11.7%
- After a month
- 6 up, 6 down typical move ±14.0%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 5, 2026 | −11.2% | −0.4% | −5.3% | −4.8% |
| May 6, 2026 | +23.2% | +1.1% | +25.8% | +25.6% |
| February 25, 2026 | +2.8% | +0.3% | −5.5% | −7.8% |
| November 5, 2025 | −8.1% | −0.7% | +5.0% | +17.5% |
| August 6, 2025 | +13.9% | +0.7% | +24.5% | +36.0% |
| May 7, 2025 | +25.3% | +1.1% | +23.9% | +30.7% |
| February 25, 2025 | −16.3% | −0.4% | −16.0% | −19.4% |
| October 30, 2024 | −2.5% | −2.3% | −1.6% | −0.9% |
| July 31, 2024 | −5.8% | +0.2% | −12.9% | −2.1% |
| May 1, 2024 | +12.9% | +0.6% | +11.9% | +9.5% |
| February 21, 2024 | +6.9% | +2.2% | +4.7% | +7.0% |
| November 1, 2023 | −0.8% | +3.0% | −3.8% | −6.4% |
Fundamentals
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Cardiopulmonary | $785M | 57.0% | ▲ 14.9% |
| Neuromodulation | $593M | 43.0% | ▲ 7.0% |
| Region | Revenue | YoY |
|---|---|---|
| United States | $740M | ▲ 6.4% |
| Locations Excluding The United States and Europe | $379M | ▲ 12.1% |
| Europe | $269M | ▲ 22.3% |
| United Kingdom | $55.9M | ▲ 14.3% |
These categories overlap or exclude eliminations, so shares aren't shown.
From Livanova PLC's 10-K filed February 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Who owns it
Funds buying and selling- Reported value
- $4.9B
- Institutions reporting
- 302
- Shares held vs prior quarter
- ▲ 1.0%
- Positions opened / closed
- 48 / 36
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Blackrock, Inc. | $622M | 7.6M | 12.8% | ▲ 6.0% |
| Primecap Management Co | $343M | 4.2M | 7.0% | ▼ 0.9% |
| FMR LLC | $259M | 3.1M | 5.3% | ▲ 18.0% |
| Hood River Capital Management LLC | $211M | 2.6M | 4.3% | ▲ 303.0% |
| AQR Capital Management LLC | $191M | 2.4M | 3.9% | ▼ 5.5% |
| Invesco Ltd. | $184M | 2.2M | 3.8% | ▲ 37.7% |
| Artisan Partners Limited Partnership | $183M | 2.2M | 3.8% | ▲ 4.8% |
| State Street Corp | $178M | 2.2M | 3.7% | ▲ 4.5% |
| American Century Companies Inc | $166M | 2.0M | 3.4% | ▲ 12.2% |
| Dimensional Fund Advisors LP | $152M | 1.8M | 3.1% | ▲ 1.0% |
| Geode Capital Management, LLC | $144M | 1.8M | 3.0% | ▲ 17.2% |
| Wellington Management Group LLP | $143M | 1.7M | 2.9% | ▼ 8.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Livanova PLC's complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $1M 7 trades by 3 insiders · 0% under pre-set plans
Net ▼ $1M net selling
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Bianchi Francesco Director | September 10, 2026 | Sell | 3,500 | $78.01 | $273,035 |
| Story Brooke Director | September 4, 2026 | Sell | 2,300 | $81.42 | $187,266 |
| Bianchi Francesco Director | August 31, 2026 | Sell | 1,650 | $79.72 | $131,538 |
| Tezel Ahmet Chief Innovation Officer | August 11, 2026 | Sell | 2,675 | $77.74 | $207,954 |
| Bianchi Francesco Director | June 15, 2026 | Sell | 1,200 | $80.19 | $96,228 |
| Bianchi Francesco Director | May 26, 2026 | Sell | 1,800 | $75.75 | $136,350 |
| Story Brooke Director | November 18, 2025 | Sell | 250 | $53.94 | $13,485 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Next expected around November 4, 2026 estimated from the company's past filing pattern, not announced
- August 5, 2026
- May 6, 2026
- February 25, 2026
- November 5, 2025
- August 6, 2025
- May 7, 2025
Recent SEC filings
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- DEF 14A Proxy statement
- 10-K Annual report
- 8-K Current report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Livanova PLC in brief
- What does Livanova PLC do?
- Livanova PLC is a US-listed company in the health care equipment industry. Its financial year ends in December.
- What is Livanova PLC's stock ticker?
- Livanova PLC trades under the ticker LIVN on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Livanova PLC's largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Primecap Management Co and FMR LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Livanova PLC stock?
- Over the last 12 months, Livanova PLC's directors and officers reported 0 open-market purchases and 7 sales on Form 4. The insider trading page charts every trade.
- When is Livanova PLC's next earnings date?
- Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Livanova PLC announces its own schedule.
Follow research on Livanova PLC
New research on the companies we cover arrives in the weekly email. Free, one email a week.